V
Viracta Therapeutics D
D
VIRX
0.16000
USD
0.00
(1.91%)
مغلق
حجم التداول
700
الربح لكل سهم
0
العائد الربحي
0
P/E
-0
حجم السوق
6,306,747
المقالات
العنوان: Viracta Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.